Nexina Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-06-2024
- Paid Up Capital ₹ 0.40 M
as on 23-06-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 92.31%
(FY 2022)
- Profit 73.95%
(FY 2022)
- Ebitda 194.70%
(FY 2022)
- Net Worth 106.76%
(FY 2022)
- Total Assets 34.05%
(FY 2022)
About Nexina Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Rajni Kulhar, Yogendra Parashar, Nidhi Awasthi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MP2018PTC046490
- Company No.
046490
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Sep 2018
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nexina Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vanita Parashar  | Managing Director | 07-Sep-2018 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajni Kulhar | Director | 04-Jan-2019 | Current |
| Yogendra Parashar | Director | 29-May-2021 | Current |
| Nidhi Awasthi | Director | 04-Jan-2019 | Current |
Financial Performance of Nexina Life Sciences.
Nexina Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 92.31% increase. The company also saw a substantial improvement in profitability, with a 73.95% increase in profit. The company's net worth Soared by an impressive increase of 106.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexina Life Sciences?
In 2022, Nexina Life Sciences had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nexina Cdcare Private LimitedActive 3 years 2 monthsYogendra Parashar, Nidhi Awasthi and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nexina Life Sciences?
Nexina Life Sciences has a workforce of 36 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexina Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexina Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
